Dr. Gautam Ghatnekar
Principal investigator, leads FirstString Research, Inc and FIRSTSTRING RESEARCH INC.
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$3.3MFederal grants as PI6 awards
1Patents grantedLatest Oct 20, 2015
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
6 awards · $3.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 17, 2021 | DoD | SBIR Phase II A novel peptide-based topical therapeutic to promote corneal regeneration and restore corneal biomechanics following blast and burn injuries | $1.5M | FIRSTSTRING RESEARCH INC |
| Jun 17, 2021 | DoD | SBIR Phase II A novel peptide-based topical therapeutic to promote corneal regeneration and restore corneal biomechanics following blast and burn injuries | $1.5M | FirstString Research, Inc |
| Apr 15, 2019 | NIH | SBIR Phase I Evaluation of a Novel Connexin-Based Peptide in the Treatment of Combined Ionizing Radiation and Thermal Burn Injury | $300K | FIRSTSTRING RESEARCH INC |
| Apr 15, 2019 | NIH | SBIR Phase I Evaluation of a Novel Connexin-Based Peptide in the Treatment of Combined Ionizing Radiation and Thermal Burn Injury | $300K | FirstString Research, Inc |
| Sep 1, 2017 | NIH | SBIR Phase I Evaluation of a Connexin based Peptide for the Treatment of Age Related Macular Degeneration | $225K | FIRSTSTRING RESEARCH INC |
| Sep 1, 2017 | NIH | SBIR Phase I Evaluation of a Connexin based Peptide for the Treatment of Age Related Macular Degeneration | $225K | FirstString Research, Inc |
| Aug 15, 2017 | NIH | SBIR Phase II Evaluation of a Novel Connexin-Based Peptide for the Treatment of Diabetic Wounds | $1.0M | FIRSTSTRING RESEARCH INC |
| Aug 15, 2017 | NIH | SBIR Phase II Evaluation of a Novel Connexin-Based Peptide for the Treatment of Diabetic Wounds | $1.0M | FirstString Research, Inc |
| Aug 4, 2016 | NIH | SBIR Phase I Stabilization of gap/tight junctions to ameliorate brain death induced endothelial cell injury | $225K | FIRSTSTRING RESEARCH INC |
| Aug 4, 2016 | NIH | SBIR Phase I Stabilization of gap/tight junctions to ameliorate brain death induced endothelial cell injury | $225K | FirstString Research, Inc |
| Sep 28, 2015 | DoD | SBIR Phase I A Novel Peptide-based Topical Therapeutic to Promote Corneal Regeneration and Restore Corneal Biomechanics Following Blast and Burn Injuries | $100K | FIRSTSTRING RESEARCH INC |
| Sep 28, 2015 | DoD | SBIR Phase I A Novel Peptide-based Topical Therapeutic to Promote Corneal Regeneration and Restore Corneal Biomechanics Following Blast and Burn Injuries | $100K | FirstString Research, Inc |
2 patents as inventor
- US 9161984FIRSTSTRING RESEARCH INCOct 20, 2015
- US FIRSTSTRING RESEARCH INC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#524
Awards as PI#315
Patents#155
Companies
- FirstString Research, IncLeads (SEC Form D) · Biotech
- FIRSTSTRING RESEARCH INCLeads (SEC Form D)
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.